The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Cited by (201)

Items 101–200 of 201

1. Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib
   Iván González, Deyali Chatterjee · 2019 · ACG Case Reports Journal
2. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
   J.L. González-Larriba, Martín Lázaro-Quintela, Manuel Cobo, Manuel Dómine, Margarita Majem, Rosario García‐Campelo · 2017 · Translational Lung Cancer Research
3. Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
   Yalan Wu, Ruizhan Tong, Yan Zhang, Binbin Hu, Ke Zheng, Zhenyu Ding, Feng Peng, Youling Gong, Yongmei Liu, You Lü · 2017 · OncoTargets and Therapy
4. Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration
   Jennifer Arney, Ashley Helm, Travis W. Crook, Ursula K. Braun, G. John Chen, Teresa Gray Hayes · 2017 · Lung Cancer
5. Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer
   Yudong Wang, Zhijie Wang, Sarina Anne Piha-Paul, Filip Jankú, Vivek Subbiah, Naiyi Shi, Kenneth R. Hess, Russell R. Broaddus, Baoen Shan, Aung Naing et al. · 2018 · Oncotarget
6. Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model
   Huixi Zou, Yufeng Zhang, Dafang Zhong, Yong Jiang, Fei Liu, Qianyu Zhao, Zhong Zuo, Yifan Zhang, Xiaoyu Yan · 2021 · Acta Pharmacologica Sinica
7. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
   Yan-Jei Tang, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu · 2022 · Cancers
8. EGFR T751_I759delinsN Mutation in Exon19 Detected by NGS but Not by Real-Time PCR in a Heavily-Treated Patient with NSCLC
   Zi‐Ting Chang, Tien‐Ming Chan, Chiao‐En Wu · 2022 · International Journal of Molecular Sciences
9. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report
   Takehiro Uemura, Tetsuya Oguri, Minami Okayama, Hiromi Furuta, Yoshihiro Kanemitsu, Osamu Takakuwa, Hirotsugu Ohkubo, Masaya Takemura, Ken Maeno, Yutaka Ito et al. · 2017 · Molecular and Clinical Oncology
10. Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation–Positive NSCLC
    Ofer Shamni, Hilbert Grievink, Batel Itamar, Eyal Mishani, Galith Abourbeh · 2018 · Molecular Imaging and Biology
11. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer
    Runbo Zhong, Jianlin Xu, Yuqing Lou, Tianqing Chu, Hua Zhong, Baohui Han · 2020 · Annals of Palliative Medicine
12. Synthesis and evaluation of a rociletinib analog as prospective imaging double mutation L858R/T790M in non-small cell lung cancer
    Muammar Fawwaz, Kenji Mishiro, Bambang Purwono, Ryuichi Nishii, Kazuma Ogawa · 2023 · Journal of Pharmacy & Pharmacognosy Research
13. The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy
    Yanjing Peng, Jinjing Tan · 2023 · Frontiers in Bioscience-Landmark
14. Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population
    Nora Berois, Diego Touya, Luis Ubillos, Bernardo Bertoni, Eduardo Osinaga, Mario Varangot · 2017 · Journal of Cancer Epidemiology
15. Dynasore-induced potent ubiquitylation of the exon 19 deletion mutant of epidermal growth factor receptor suppresses cell growth and migration in non-small cell lung cancer
    Taishu Wang, Duchuang Wang, Yue Zhang, Jinrui Zhang, Xiuna Sun, Yue Wu, Shanshan Wang, Yang Zhang, Lu Xu, Qingxia Kong et al. · 2018 · The International Journal of Biochemistry & Cell Biology
16. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
    Pathmanathan Rajadurai, Phaik‐Leng Cheah, Soon Hin How, Chong Kin Liam, Muhammad Azrif Ahmad Annuar, Norhayati Omar, Noriah Othman, Nurhayati Mohd Marzuki, Yong Kek Pang, Ros Suzanna Bustamam et al. · 2019 · Lung Cancer
17. ZNF655 is involved in development and progression of non-small-cell lung cancer
    Zhihua Teng, Jie Yao, Ling Zhu, Lufeng Zhao, Gang Chen · 2021 · Life Sciences
18. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study
    Giannis Mountzios, Anna A. Koumarianou, Alexandros Bokas, Dimitriοs Mavroudis, Epaminondas Samantas, Evangelos Fergadis, Helena Linardou, Panagiotis Katsaounis, Elias Athanasiadis, Michalis V. Karamouzis et al. · 2021 · Cancers
19. Combining EGFR Inhibitors With SHP2 Or LSD1 Inhibitors to Overcome Multidrug Resistance in Cancer
    Huiqing Zhang, Xinyu Yang, Yihui Song, Bin Yu · 2022 · Future Medicinal Chemistry
20. [Preliminary Study on Detection of Circulating Tumor Cells in Lung Cancer by EGFR/Vimentin/Folic Acid Magnetic Sphere].
    Guolei Li, Yun Wang, Guoliang Tan, Yuan Liu, Xu Zhao, Hao Feng, Wei Xing, Zhi-Feng Xu · 2020 · PubMed Central
21. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation
    Kazutoshi Isobe, Atsushi Kakimoto, TETSUO MIKAMI, Kyohei Kaburaki, Hiroshi Kobayashi, TAKAHIRO YOSHIZAWA, TAKASHI MAKINO, HAJIME OTSUKA, Go Sano, Keishi Sugino et al. · 2016 · Cancer Genomics & Proteomics
22. Method for preservation of DNA stability of liquid-based cytology specimens from a lung adenocarcinoma cell line
    Yukiko Matsuo, Kazuya Yamashita, Tsutomu Yoshida, Yukitoshi Satoh · 2020 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
23. Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone?
    Xingni Tang, Yichao Shen, Yinnan Meng, Liqiao Hou, Chao Hui ZHOU, Changhui Yu, Haijian Jia, Wei Wang, Ge Ren, Jing Cai et al. · 2021 · Annals of Palliative Medicine
24. From Lung Cancer Screening to Targeted Therapies: The Endless Race against Lung Cancer Morbidity and Mortality
    Alexander G. Mathioudakis, Georgia F. Hardavella · 2018 · Journal of Lung Cancer
25. Design, synthesis and evaluation of N-hydroxypropenamides based on adamantane to overcome resistance in NSCLC
    Xuefei Bao, Yuhong Sun, Changshun Bao, Jiayu Zhang, Shenglan Zou, Jingyu Yang, Chunfu Wu, Lihui Wang, Guoliang Chen · 2019 · Bioorganic Chemistry
26. Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors
    Yiyang Wang, Difan Zheng, Jizhuang Luo, Jie Zhang, Cecilia Pompili, Hideki Ujiie, Natsumi Matsuura, Haiquan Chen, Feng Yao · 2021 · Translational Lung Cancer Research
27. Identification of FUT7 hypomethylation as the blood biomarker in the prediction of early-stage lung cancer
    Rong Qiao, Feifei Di, Jun Wang, Yujie Wei, Xu Tian, Liping Dai, Wanjian Gu, Baohui Han, Rongxi Yang · 2023 · Journal of genetics and genomics/Journal of Genetics and Genomics
28. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma
    Yunhui Qu, Xiuzhi Zhang, Rong Qiao, Feifei Di, Yakang Song, Jun Wang, Longtao Ji, Jie Zhang, Wanjian Gu, Yifei Fang et al. · 2024 · Respiratory Research
29. Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors
    Antonio Pannuti, Aleksandra Filipović, Chindo Hicks, Elliot J. Lefkowitz, Travis Ptacek, Justin Stebbing, Lucio Miele · 2018 · PLoS ONE
30. Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation
    Fei Cao, Chao Wan, Lin Xie, Han Qi, Lujun Shen, Shuanggang Chen, Ze Song, Weijun Fan · 2019 · Thoracic Cancer
31. Combined identification of LncRNA CCAT1 and SOX2OT in serum as an effective screening for non-small cell lung cancer.
    Zhipeng Wang, Jian Li, Yan H. Wu, Hongbin Wang · 2019 · Europe PMC (PubMed Central)
32. Integrating network pharmacology and bioinformatics analysis to explore the mechanism of Yupingfengsan in treating lung adenocarcinoma
    Liping Shen, Wanqing Chen, Bo Zhang, Lingshuang Liu, Yajuan Cao · 2019 · European Journal of Integrative Medicine
33. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
    Kazutoshi Isobe, Atsushi Kakimoto, Tetuo Mikami, Kyohei Kaburaki, Hiroshi Kobayashi, Takahiro Yoshizawa, Yuta Nakano, Takashi Makino, Hajime Otsuka, Go Sano et al. · 2018 · Oncology Reports
34. Research progress of LSD1-based dual-target agents for cancer therapy
    Xiaojuan Yang · 2024 · Bioorganic & Medicinal Chemistry
35. Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer
    Chang Dong Yeo, In Kyoung Kim, Woo Ho Ban, Hye Seon Kang, Jin Woo Kim, Seung Joon Kim, Jong Y. Park, Sang Haak Lee · 2019 · Translational Cancer Research
36. Synthesis and initial in vitro evaluation of olmutinib derivatives as prospective imaging probe for non-small cell lung cancer
    Muammar Fawwaz, Kenji Mishiro, Arwansyah Arwansyah, Ryuichi Nishii, Kazuma Ogawa · 2023 · Bioimpacts
37. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
    Myung‐Ju Ahn, Ji‐Youn Han, Dong‐Wan Kim, Byoung Chul Cho, Jin Hyoung Kang, Sang-We Kim, James Chih‐Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee · 2019 · Cancer Research and Treatment
38. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma
    Seung-Myoung Son, Chang Gok Woo, Hye Sook Han, Ki Hyeong Lee, Young Hyun Lim, Ok-Jun Lee · 2020 · Clinical Chemistry and Laboratory Medicine (CCLM)
39. The value of AGR2 and KRT5 as an immunomarker combination in distinguishing lung squamous cell carcinoma from adenocarcinoma.
    Bo Pan, Zixin Wei, Juxuan Zhang, Xin Li, Qingwei Meng, Yingyue Cao, Lishuang Qi, Yan Yu · 2021 · PubMed Central
40. Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
    Hanping Wang, Li Zhang, Xiaoyan Si, Xiaotong Zhang, Mengzhao Wang · 2018 · OncoTargets and Therapy
41. The prospect of patritumab for treating non-small cell lung cancer
    Hidehito Horinouchi · 2016 · Expert Opinion on Biological Therapy
42. FNC inhibits non-small cell lung cancer by activating the mitochondrial apoptosis pathway
    Jing Xiang, Shuai Niu, Yi Liang, Huiping Chen, Ning Wang, Youmei Peng, Fang Ma, Wanying Yue, Qingduan Wang, Junbiao Chang et al. · 2021 · Genes & Genomics
43. Image‐guided thermal ablation for patients with epidermal growth factor receptor‐mutant nonsmall cell lung cancer
    Yahan Huang, Yongmei Kong, Zhigang Wei, Xin Ye · 2022 · Asia-Pacific Journal of Clinical Oncology
44. Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients
    Guan‐Yuan Chen, Sheng‐Kai Liang, Yu-Feng Wei, Te-I Weng, Kuan‐Yu Chen · 2023 · Analytical Biochemistry
45. Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI
    Beisheng Yang, Chunli Luo, Min Yu, Lin Zhou, Tao Bo, Biqiu Tang, Ying Zhou, Jiang Zhu, Meijuan Huang, Feng Peng et al. · 2021 · Frontiers in Oncology
46. Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma
    Elio Gregory Pizzutilo, Calogero Lauricella, Giulio Cerea, Laura Giuseppina Giannetta, Gianluca Tomasello, Stefano Stabile, Valentina Motta, Spyridon Alexiadis, Francesco Scaglione, Angelo Vanzulli et al. · 2019 · JCO Precision Oncology
47. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Chi Wang, Yun Li, Li Ke, Lejie Cao, Pingsheng Fan, Zhiwei Wu, Quan Wu · 2019 · Journal of Cancer
48. An Overview of Promising Biomarkers in Cancer Screening and Detection
    Saba Hasan · 2020 · Current Cancer Drug Targets
49. Molecular Diagnosis and Targeting for Lung Cancer
    Kazue Yoneda, Fumihiro Tanaka · 2017 · Current human cell research and applications
50. AZD3759 for CNS metastases in EGFR-mutant lung cancer
    David Planchard · 2017 · The Lancet Respiratory Medicine
51. Central IRB Review Is an Essential Requirement for Cancer Clinical Trials
    Lowell E. Schnipper · 2017 · The Journal of Law Medicine & Ethics
52. Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan‐Tumor
    Zi Wang, Lin Chen, Wei Rao, Baoshan Cao, Muyan Cai, Xiangshan Fan, Yuan Ji, Yaqi Li, Yan Song, Sun Y et al. · 2026 · Cancer Innovation
53. Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
    Yipu Zhao, Yong Long · 2022 · Current Medical Research and Opinion
54. Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation
    Tetsuya Mitsudomi · 2017 · The Lancet Respiratory Medicine
55. The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients
    Zahra Abrehdari-Tafreshi, Ehsan Arefian, Nasser Rakhshani, S. Mahmoud A. Najafi · 2024 · Biochemical Genetics
56. Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer
    Ching-Fu Weng, Po-Ju Chen, Ailun Heather Tseng, Shih‐Hung Huang, Henry Hsin‐Chung Lee · 2019 · World Journal of Surgical Oncology
57. What is Currently the Best for Adenocarcinoma without Driver Mutation?
    Cheol‐Kyu Park, In‐Jae Oh, Young‐Chul Kim · 2018 · Tuberculosis & respiratory diseases
58. Effect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo
    Zhi Wang, Zefang Yu, Lingzhi Fang, Jing An, Chaojun Xue, Xin Zhou, Xiao Li, Ying Li, Zhanjun Dong · 2024 · Journal of Chromatography B
59. Apatinib with EGFR-TKIs in advanced wild gene-type NSCLC
    Yuanpeng Wu, Ji-Jin Wu, Shumei Tian, Tao Jin, Chan Li, Ke Xie · 2019 · Medicine
60. Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age
    Akihiko Miyanaga, Mari Masuda, Tesshi Yamada · 2019 · Springer eBooks
61. Clinical and Investigational Applications of Liquid Biopsy in Non-Small Cell Lung Cancer
    David Pérez-Callejo, Mar韆 Torrente, Atocha Romero, Mariano Provencio · 2016 · Journal of Tumor
62. Bestimmung molekularer Biomarker in der Behandlung solider Tumoren
    Nicole Pfarr, Katja Specht, Wilko Weichert · 2017 · Forum
63. Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer
    Yanxi Han, Rui Zhang, Guigao Lin, Kuo Zhang, Jiehong Xie, Jinming Li · 2017 · The Oncologist
64. FNC Inhibits Proliferation and Metastasis of Non-Small-Cell Lung Cancer in Vivo and In Vitro
    Jing Xiang, Shuai Niu, Yi Liang, Huiping Chen, Ning Wang, Youmei Peng, Fang Ma, Wanying Yue, Qingduan Wang, Junbiao Chang et al. · 2021 · Research Square
65. Determination of furmonertinib in human plasma and cerebrospinal fluid by UPLC-MS/MS: Application in lung cancer patients with and without brain metastasis
    Hongxin Qie, Cong Song, Yu-xiang Xu, Haopeng Zhao, Wenlin Gong, Peiyuan Wang, Xiaonan Gao, Jinglin Gao, Zhangying Feng, Mingxia Wang · 2024 · Journal of Chromatography B
66. Mutation-Dependent Conformational Dynamics and Dual-Mode Afatinib Binding in EGFR Exon 19 Variants
    K. Bhanja, Rajesh Ghosh, Niladri Patra · 2026 · The Journal of Physical Chemistry B
67. Genomic Applications in Pulmonary Malignancies
    Reinhard Büttner, Margarete Odenthal, Sabine Merkelbach‐Bruse · 2014 · Springer eBooks
68. Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature
    Xin Li, Shijiang Xing, Qiumei Dong · 2017 · Oncotarget
69. Recherche de la mutation T790 M : savoir persévérer
    Héloïse Bourien, Alexandra Lespagnol, Arnaud Prigent, Guillaume Leveiller, H. Léna, Charles Ricordel, R. Corre · 2018 · Revue des Maladies Respiratoires
70. Genomic Applications in Pulmonary Malignancies
    Reinhard Büttner, Carina Heydt, Sabine Merkelbach‐Bruse · 2018 · Springer eBooks
71. Molecular pathology
    Philippe Tanière, Brendan O’Sullivan, Matthew Evans, Frances Hughes · 2019 · Elsevier eBooks
72. Osimerinib haematological toxicities in non-small cell lung cancer: a randomised controlled trials meta-analysis
    Fangfang Xiong, Yunzhu Shen, Ting Liu, Yin Zhang, Xuehui Jiang · 2024 · BMJ Supportive & Palliative Care
73. Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
    Wan Ling Tan, Daniel Shao-Weng Tan · 2018 · Translational Lung Cancer Research
74. The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis
    Xiaoshun Shi, Fuxi Huang, Allen Menglin Chen, Zhuolin Wu, Qianqian Huang, Ying Liang, Qipeng Zhou, Haiyun Mo, Xiaoxiang Li, Jiexia Zhang · 2017 · Open Journal of Genetics
75. Fundamental Concepts in the Application of Plasma Genotyping (Liquid Biopsy) to EGFR Mutation Detection in Non–Small-Cell Lung Cancer
    Adrian Gerold Sacher · 2018 · JCO Precision Oncology
76. Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy
    Zhaoqian Liu, Chen‐Xue Mao, Ji‐Ye Yin · 2020 · Springer eBooks
77. Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Annemarie Fernandes Shepherd, Isabel Ruth Preeshagul, Narek Shaverdian, Abraham Jing-Ching Wu, Daphna Y. Gelblum, Daniel Richard Gomez, Andreas Rimner, Charles B. Simone · 2020 · Annals of Translational Medicine
78. Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
    Yue Fang, Qiankun Zhang, Weimin Wang, Juanjuan Tong, Xialin Li · 2023 · Frontiers in Oncology
79. Liquid biopsy in the practice of neo-oncology
    Smadar Geva, Laila C. Roisman, Nir Peled · 2016 · Journal of Thoracic Disease
80. Prise en charge des métastases cérébrales des carcinomes bronchiques
    Jordi Remón, Jihene Lahmar, Frederic G Dhermain, Benjamin Besse · 2016 · Revue des Maladies Respiratoires Actualités
81. SC31.01 The Role of Scientific Organizations
    Paul A. Bunn · 2017 · Journal of Thoracic Oncology
82. Métastases cérébrales des cancers bronchiques non à petites cellules (CBNPC)
    I. Monnet · 2017 · Revue des Maladies Respiratoires Actualités
83. Prise en charge des métastases cérébrales des cancers bronchiques non à petites cellules
    P. Noach, R. Descourt, Gilles Quéré · 2018 · Revue des Maladies Respiratoires Actualités
84. Use of a plasma test for verifying epidermal growth factor receptor gene (EGFR) mutations in fluid samples from non-small cell lung cancer patients
    Wataru Ogura, Kouki Ohtsuka, Masachika Fujiwara, Ryota Tanaka, Kumiko Sekiguchi, Hiroaki Ohnishi, Takashi Watanabe · 2020 · Respiratory Medicine Case Reports
85. PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer
    Yuliia Moskalenko, I. О. Vуnnуchenko, О. М. Smorodska, О. І. Vynnychenko, Roman Moskalenko · 2019 · Likarska sprava
86. Molecular mechanisms of lung cancer
    О. Э. Лосев, В. Б. Бородулин, Русецкая Наталья Юрьевна, Е. В. Бобылева, Бородулин Ярослав Владимирович · 2021 · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia»
87. Development of Precision Medical Technology and its Current Clinical Applications
    Kaiye Gao, Ziwen Wang, Yuanying Chi, Rui Peng · 2021 · Recent Patents on Engineering
88. Immune Therapy: What Can We Learn From Acquired Resistance?
    Michael J. Grant, Katerina A. Politi, Scott N. Gettinger · 2021 · Current cancer research
89. Targeted Treatments for Common Solid Tumors
    Elaine Vickers PhD · 2018 · Wiley eBooks
90. Faculty Opinions recommendation of Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Minesh P. Mehta · 2018 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
91. A Computer Tomography Radiomics-based model to Predict Survival of Patients with EGFR‑Mutated Non‑small‑cell Lung Cancer
    Chen Huang, Yubin Cao, Lei Zhu, Qunli Xiong, Qin Zhang · 2022 · Research Square
92. Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics
    Hoang Lam Nguyen, Ram Krishna Gupta, Tuan Anh Nguyen · 2022 · Elsevier eBooks
93. ปจจยทมความสมพนธตอการเกดการกลายพนธของยนเอพเดอรมอลโกรทแฟกเตอรรเซบเตอรชนดทตยภมแบบ T790M ในผปวยโรคมะเรงปอดชนดเซลลทขนาดไมเลกทมการกลายพนธของยนอจเอฟอารภายหลงทไดรบยาตานอจเอฟอารไทโรซนไคเนส
    ณิชา ซึงสนธิพร · 2020
94. Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach
    Mohana Roy, Sukhmani Kaur Padda · 2023 · Elsevier eBooks
95. Drug Resistance and Novel Targets for Cancer Therapy
    Popat B Mohite, Abhijeet Vishnu Puri, Shubham V. Munde, Riteshkumar Patil, Sudarshan Singh · 2025 · Interdisciplinary biotechnological advances
96. Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis
    Zichun Yuan, Yan Mei, Tongtong Wu, Gan‐Lin Zhang, Guowang Yang, Xiaomin Wang · 2025 · Frontiers in Pharmacology
97. Additional file 1 of Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy
    Kim, Yoonjung, Shin, Saeam, Kyunga Lee · 2021 · Figshare
98. Additional file 1 of OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level
    Xu, Quan, Zhai, Jin-Cheng, Huo, Cai-Qin, Li, Yang, Dong, Xue-Jiao, Li, Dong-Fang, Huang, Ru-Dan, Shen, Chuang, Chang, Yu-Jun, Zeng, Xi-Ling et al. · 2020 · Figshare
99. Additional file 1 of Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma
    Qu, Yunhui, Zhang, Xiuzhi, Rong Qiao, Feifei Di, Yakang Song, Wang, Jun, Ji, Longtao, Zhang, Jie, 顾万建, Yifei Fang et al. · 2024 · Figshare
100. Foundations of Cancer and Parenteral Oncology Therapies
     Fernando Moreira · 2026 · Advances in computational intelligence and robotics book series